| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | temsirolimus | GDSC1000 | pan-cancer | AAC | -0.051 | 0.1 |
| mRNA | quizartinib | CTRPv2 | pan-cancer | AAC | 0.061 | 0.1 |
| mRNA | tacrolimus | CTRPv2 | pan-cancer | AAC | 0.057 | 0.1 |
| mRNA | silmitasertib | CTRPv2 | pan-cancer | AAC | 0.062 | 0.1 |
| mRNA | ruxolitinib | GDSC1000 | pan-cancer | AAC | 0.05 | 0.1 |
| mRNA | BRD-K19103580 | CTRPv2 | pan-cancer | AAC | 0.06 | 0.1 |
| mRNA | compound 1B | CTRPv2 | pan-cancer | AAC | -0.062 | 0.1 |
| mRNA | BRD4132 | CTRPv2 | pan-cancer | AAC | 0.061 | 0.1 |
| mRNA | dacarbazine | CTRPv2 | pan-cancer | AAC | 0.051 | 0.1 |
| mRNA | HG-5-88-01 | GDSC1000 | pan-cancer | AAC | 0.068 | 0.1 |